Display options
Cite
Mahmoud GS, Sayed SA, Abdelmawla SN, et al. Positive effects of systemic sodium benzoate and olanzapine treatment on activities of daily life, spatial learning and working memory in ketamine-induced rat model of schizophrenia. Int J Physiol Pathophysiol Pharmacol. 2019;11(2):21-30
Mahmoud, G. S., Sayed, S. A., Abdelmawla, S. N., & Amer, M. A. (2019). Positive effects of systemic sodium benzoate and olanzapine treatment on activities of daily life, spatial learning and working memory in ketamine-induced rat model of schizophrenia. International journal of physiology, pathophysiology and pharmacology, 11(2), 21-30.
Mahmoud, Ghada S, et al. "Positive effects of systemic sodium benzoate and olanzapine treatment on activities of daily life, spatial learning and working memory in ketamine-induced rat model of schizophrenia." International journal of physiology, pathophysiology and pharmacology vol. 11,2 (2019): 21-30.
Mahmoud GS, Sayed SA, Abdelmawla SN, Amer MA. Positive effects of systemic sodium benzoate and olanzapine treatment on activities of daily life, spatial learning and working memory in ketamine-induced rat model of schizophrenia. Int J Physiol Pathophysiol Pharmacol. 2019 Apr 15;11(2):21-30. eCollection 2019. PMID: 31149324; PMCID: PMC6526385.
Copy Download .nbib Format: NLM
Share it on

Int J Physiol Pathophysiol Pharmacol. 2019 Apr 15;11(2):21-30. eCollection 2019.

Positive effects of systemic sodium benzoate and olanzapine treatment on activities of daily life, spatial learning and working memory in ketamine-induced rat model of schizophrenia.

International journal of physiology, pathophysiology and pharmacology

Ghada S Mahmoud, Sally A Sayed, Shehabeldin N Abdelmawla, Mohamed A Amer

Affiliations

  1. Department of Medical Physiology, Faculty of Medicine, Assiut University Assiut, Egypt.
  2. Faculty of Medicine, Assiut University Assiut, Egypt.
  3. Faculty of Medicine, Aswan University Aswan, Egypt.

PMID: 31149324 PMCID: PMC6526385

Abstract

BACKGROUND: Sodium Benzoate (SB) significantly improved positive, negative, and cognitive symptoms as add on treatment in schizophrenia. Olanzapine (Ola), the most effective atypical antipsychotic drug, has been linked to hepatic steatosis, acute kidney injury, reproductive side effects and poor effect on negative symptoms in some patients.

GOALS: is to compare the efficacy and check the safety of long-term monotherapy with SB 0.01 mg/Kg versus Ola on male cognitive, memory, hepatic, renal and testicular functions in rat model of schizophrenia.

METHODS: 48 young adult male rats were divided into 6 groups; C: control; O: received Ola; SB: received SB; K: received single IP ketamine (Ket) injection; K+O: received Ola and Ket and K+SB: received SB and Ket. Ola and SB given orally for 3 or 10 weeks for behavioral or serological studies respectively. We measured activities of daily life (ADL), spatial learning and memory in radial arm water maze (RAWM), serum parameters of hepatic, renal and testicular functions.

RESULTS: Both Ola and SB significantly improved hoarding and burrowing, caused significant decrease in time to reach target (TRT), working memory errors (WME) in K+O and K+SB groups compared to K group. Ola caused significant increase in ALT, AST and creatinine and decrease in serum LH, testosterone compared to controls. SB caused significant rise in serum LH, ALT, AST and decrease in protein and albumin compared to both C and O groups.

CONCLUSION: Both Ola and SB improved ADL, cognitive and memory functions. Although SB saved testicular and renal functions, it worsened liver function compared to Ola.

Keywords: Schizophrenia; activities of daily life (ADL); kidney; liver; olanzapine (ola); radial arm water maze (RAWM); sodium benzoate (sb); testis

Conflict of interest statement

None.

References

  1. Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:55-68 - PubMed
  2. Neuropsychopharmacology. 2007 Mar;32(3):719-27 - PubMed
  3. Nat Protoc. 2006;1(4):1671-9 - PubMed
  4. Neuroscience. 2008 Oct 28;156(4):1005-16 - PubMed
  5. Psychoneuroendocrinology. 2009 Jan;34(1):129-39 - PubMed
  6. J Ind Hyg Toxicol. 1948 Jan;30(1):63-8 - PubMed
  7. Mol Pharmacol. 2010 Mar;77(3):317-26 - PubMed
  8. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654 - PubMed
  9. Neuropsychopharmacology. 2012 Jan;37(1):4-15 - PubMed
  10. Prim Care Companion CNS Disord. 2011;13(3):null - PubMed
  11. Arzneimittelforschung. 2012 Jan;62(1):4-8 - PubMed
  12. Schizophr Bull. 2012 Sep;38(5):920-6 - PubMed
  13. PLoS One. 2013;8(2):e57308 - PubMed
  14. Ren Fail. 2013;35(5):657-9 - PubMed
  15. JAMA Psychiatry. 2013 Dec;70(12):1267-75 - PubMed
  16. J Psychopharmacol. 2014 Apr;28(4):287-302 - PubMed
  17. Compr Psychiatry. 2014 Jul;55(5):1182-7 - PubMed
  18. Front Synaptic Neurosci. 2014 May 02;6:11 - PubMed
  19. Ann Intern Med. 2014 Aug 19;161(4):242-8 - PubMed
  20. CNS Spectr. 2014 Dec;19 Suppl 1:38-52; quiz 35-7, 53 - PubMed
  21. PLoS One. 2015 Jun 23;10(6):e0130398 - PubMed
  22. Eur J Neurosci. 2016 Apr;43(7):979-89 - PubMed
  23. Drug Saf. 2016 Oct;39(10):925-43 - PubMed
  24. Neurosci Lett. 2016 Nov 10;634:42-51 - PubMed
  25. Saudi Pharm J. 2016 Nov;24(6):698-704 - PubMed
  26. World J Gastrointest Pharmacol Ther. 2017 Feb 6;8(1):26-38 - PubMed
  27. Pharmacognosy Res. 2017 Jul-Sep;9(3):247-252 - PubMed
  28. J Biochem Mol Toxicol. 2018 Feb;32(2):null - PubMed
  29. Biol Psychiatry. 2018 Sep 15;84(6):422-432 - PubMed
  30. Int J Physiol Pathophysiol Pharmacol. 2018 Mar 10;10(1):39-46 - PubMed
  31. J Biomed Sci. 2018 May 2;25(1):40 - PubMed
  32. Molecules. 2018 Aug 20;23(8):null - PubMed
  33. Int J Mol Sci. 2018 Oct 10;19(10):null - PubMed

Publication Types